Targeting Myelogenous Leukemia Stem Cells: Role of the Circulation by Jane Liesveld
“fonc-02-00086” — 2012/8/2 — 10:42 — page 1 — #1
REVIEW ARTICLE
published: 02 August 2012
doi: 10.3389/fonc.2012.00086
Targeting myelogenous leukemia stem cells: role
of the circulation
Jane Liesveld*
Hematology/Oncology Division, University of Rochester, Rochester, NY, USA
Edited by:
Michael R. King, Cornell University,
USA
Reviewed by:
JoelWojciechowski, Balance
Engineering LLC, USA
Srinivas Narasipura, Rush University,
USA
*Correspondence:
Jane Liesveld, Hematology/Oncology
Division, University of Rochester,
Box 704, 601 Elmwood Avenue,
Rochester, NY, USA.
e-mail: jane_liesveld@urmc.rochester.edu
Unlike stem cells from solid tumors, the stem cells which initiate myelogenous leukemias
arise in marrow, an organ with a unique circulation which allows ready access of leukemia
cells, including leukemia stem cells (LSCs), to the vasculature.This poses unique problems
in the targeting of LSCs since these cells are found circulating in the majority of leukemia
cases at diagnosis and are usually not detectable during remission states. Because most
cases of leukemia relapse, it is suggested that LSCs remain quiescent in the marrow
until they eventually proliferate and circulate again. This indicates that effective target-
ing of LSCs must occur not only in peripheral circulation but in the micro-circulation of
the marrow. Targeting such interactions may overcome cell adhesion-mediated treatment
resistance, other multi-drug resistance mechanisms, and opportunities for clonal evolu-
tion in the marrow environment. Targeting selectins and integrins, signal transduction
mediators, and chemokine/cytokine networks in the marrow micro-circulation may aid in
abrogating leukemia-initiating stem cells which contribute to disease relapse. LSCs pos-
sess surface antigen proﬁles and signal transduction activation proﬁles which may allow
differential targeting as compared with normal hematopoietic stem cells.
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DEFINING THE LEUKEMIA STEM CELL AND ITS IMPORTANCE
Myeloid leukemias are a group of disorders arising in marrow
and often involving blood which are characterized by overpro-
duction of immature leukocytes or terminally differentiated cells
as in chronic myelogenous leukemia (CML). In this review, we
will focus on acute leukemias where impairment of differentia-
tion is found. Most therapies available to treat acute myelogenous
leukemia target leukemia blast cells which are in general a later
progenitor/precursor cell no longer capable of self-renewal and
multipotential differentiation. Only about 0.01% of normal mar-
row cells are hematopoietic stem cells (HSCs), and what the actual
leukemia stem cell (LSC) number is at a typical new diagnosis
of acute myeloid leukemia (AML) is not known. Also, it is not
known if mutations which are associated with AML arise in nor-
mal stem cells or in more differentiated cell types which then
acquire stem-like features (Misaghian et al., 2009). Leukemia stem
cells are deﬁned functionally as cells which are able to engraft
in immunocompromised mice, but it is possible that xenotrans-
plantation underestimates the numbers and types of stem cells
due to the presence of a foreign microenvironment (Adams and
Strasser, 2008). The concept that a LSC which is a counterpart
to a normal HSC exists has been considered for many decades,
but thus far the implications that such a cell has in the manifes-
tation and therapy of acute myelogenous leukemia have remained
controversial.
The cellular origin of AML remains unclear, with ongoing con-
troversy as to whether it arises from a transformed true HSC
with multipotential self-renewal capacity or in a more mature
progenitor cell. Most AML cells do not possess the properties of
self-renewal and multipotency. This has led to the concept of stem
cell heterogeneity (Nguyen et al., 2012; Walter et al., 2012). Some
leukemias may arise at the level of pluripotent CD33− precursors,
some may have an initial mutation in a pluripotent HSC with
a collaborating mutation such as a core binding factor mutation
occurring later, or some may arise at the level of a committed
myeloid precursor as is the case in acute promyelocytic leukemia.
Both the mutation(s) leading to a leukemic state and the cell of
origin of the mutation are thought to have prognostic bearing
(Walter et al., 2012). The LSC may not always be a rare population
of quiescent cells. The phenotype, frequency, and functional prop-
erties of these cells may also change during disease progression
(Mather, 2012; Nguyen et al., 2012).
Bonnet and Dick (1997) found that only leukemic blasts
with the immature cell-surface phenotype characterized by CD34
expression with lack of CD38 expression were capable of transfer-
ring AML to immunodeﬁcient mice; severe combined immunod-
eﬁciency (SCID) mice. This seemed consistent with a cancer stem
cell (CSC) hypothesis which suggests that tumors are maintained
by a small population of stem cell-like cancer cells which have the
capability for indeﬁnite self-renewal (Lapidot et al., 1994). Subse-
quently, some leukemia-initiating cells (L-ICs) have been found
in the CD34 negative marrow fractions (Taussig et al., 2010). Also,
LSCs have a hierarchy deﬁned by length of repopulating potential
in serial immune deﬁcient mice transplantations deﬁned as short-
and long-term potential (Sarry et al., 2011). Those with long-term
potential are thought to be quiescent (outside of active cell cycle)
and express high levels of the multi-drug resistance phenotype,
MDR-1, indicating ability to efﬂux cytotoxic drugs (Krause and
van Etten, 2007). There is also evidence that pathways involved in
proliferation of primitive cells such as Hox, hedgehog, notch, and
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Wnt are all involved in the maintenance and proliferation of the
LSC (reviewed in Krause and van Etten, 2007).
While the CD34+CD38− cells are clonal as based on cyto-
genetics, ﬂuorescence in situ hybridization (FISH), and reverse
transcriptase polymerase chain reaction (RT-PCR) in some
cases, normal CD34+CD38− cells are also capable of engrafting
NOD/SCID mice and must be distinguished from their leukemic
counterparts in the course of functional assays. If a multipotential
CD34+CD38− stem cell is the cell of origin for acute leukemia, it is
not known why the lymphoid phenotype is suppressed after trans-
formation. Satoh and Ogata (2006) have postulated that myeloid
HSCs with minimal lymphopoietic potential may be the site of
transformation in AML and could be a target to eliminate the LSC
in many cases.
The LSC is best deﬁned functionally by its ability to reca-
pitulate leukemia faithfully in immunocompromised mice. This
requires not only homing and engraftment potential to themurine
microenvironment but ability to express the phenotype of the
original AML in terms of surface phenotype and of clonal mark-
ers such as chromosome translocations or deletions or of other
abnormal molecular markers such as nucleophosmin-1, Flt3–
ITD expression, or Ras mutations. Unfortunately, only about
50% of AML cases have clonal chromosome markers to allow
easy distinction, but other aberrant leukemic cell phenotypes
can sometimes allow the distinction of normal vs. leukemia
human CD45+ cells to be made by ﬂow cytometry or by muta-
tion analysis by PCR or sequencing. Detecting the presence of
human CD45+ cells is not sufﬁcient as normal HSCs are also
able to engraft immunodeﬁcient mice, so documentation of the
leukemic nature of the engrafting cells is required. In vivo L-
IC and HSC assays are important to measure functional stem
cell capability and to measure effectiveness of therapies against
L-ICs as has been determined with a compound kinetin riboside
which has potential therapeutic efﬁcacy and preferential effects
against LSCs as compared with normal HSCs (McDermott et al.,
2012). Some AML do not engraft immune deﬁcient mice, and
it is thought that murine engraftment could represent prolif-
erative potential of the leukemic cells or could simply reﬂect
ability to interact with the murine microenvironment (Risueno
et al., 2011). Targeting LSCs is thought to be of importance
since the burden of LSCs at diagnosis has prognostic signiﬁ-
cance. Patients whose blasts at diagnosis fail to engraft NOD/SCID
mice at high cell doses have superior long-term survival
(Pearce et al., 2006).
Knowing which “stem cell” to target therapeutically in AML
is difﬁcult, however, since relapse may occur in a founder clone,
a recurring subclone, or in a novel stem cell clone (Walter et al.,
2012). Not only do controversies exist about how to identify a
LSC but also about whether such a stem cell must be eliminated
in order to effectively treat the leukemia (Kelly et al., 2007; Majeti,
2011). The possibility that stem cell-like components of tumors
may change phenotype rapidly and reversibly also makes study
of these cells difﬁcult (Mather, 2012). Because of the hetero-
geneity in the phenotype of LSCs, surface antigen phenotype is
inadequate as a means of isolation. High expression of aldehyde
dehydrogenase (ALDH) activity in conjunction with CD34 has
been found to delineate an L-IC (Ran et al., 2012). The frequency
of aldehyde bright cells in the marrow at time of initial diagnosis
is an independent prognostic factor predicting overall survival
(Ran et al., 2012). It has also been shown that in a majority of
AML cases, two subsets with progenitor immunophenotype coex-
ist, and both have LSC activity and are hierarchically patterned
(Goarden et al., 2011).
That the stem cell model has clinical signiﬁcance inAML is sug-
gested by studies such as one which showed that the percentage
of CD34+CD38− LSCs at the time of diagnosis correlated with
the duration of relapse-free survival in 92 patients (van Rhenen
et al., 2005). Those with>3.5% AML LSCs had a median relapse-
free survival of 5.6 months vs. those with <3.5% who had a
median relapse-free survival of 16 months. The presence of a
CD34+CD38− ALDH intermediate population has been shown
to correlate with minimal residual disease (MRD) and subsequent
relapse and to be able to distinguish LSCs from normal stem cells
which are aldehyde high expressors (Gerber et al., 2012). Overall,
LSC frequency is thought to be an important component of MRD
(Buccisano et al., 2012).
ASSAYING THE LSC
The LSC can be assayed by ﬂow cytometry and immunopheno-
type, but given the vagaries and lack of standardization of this
technique, it is most accurately assayed by its ability to engraft
immune deﬁcient mice, although as noted above, there are both
quantitative and qualitative problems with those assays (Mather,
2012). TheL-IC is able to recapitulate thephenotypeof theoriginal
leukemia when transplanted into NOD/SCID mice and then to be
secondarily transplanted to another sublethally irradiated mouse.
The NOD/SCID xenograft has no B or T cells, and leukemia
engraftment is often quite low and requires transplantation of
thousands of cells. In the NOD/SCID/IL-2Rγ−/− (NSG) species,
NK cells are also deﬁcient and as few as 100 cells will transplant
the leukemia (Ishikawa et al., 2005). ALDH has been utilized as a
marker of LSCs, and in vitro long-term culture assays have been
reported to identify an L-IC (Sutherland et al., 2001).
Initially, it was thought that the LSC resided in the
CD34+CD38− compartment, but many anti-CD38 antibodies,
including those utilized in the original isolation of LSCs inhibit
engraftment of CD34+CD38+ leukemia cells through an Fc-
dependent mechanism (Taussig et al., 2008). Blockade of Fc
receptors can result in engraftment of CD38+ AML cells, sug-
gesting that CD38+ fractions may contain LSCs (Taussig et al.,
2008). Also, in some AML cases with nucleophosmin mutation,
the L-ICs reside in theCD34negative fraction (Taussig et al., 2010).
Table 1 illustrates some of the characteristics of AML stem cells as
contrasted with normal HSCs.
MEANS TO TARGET LSCs
TARGETING CELL-SURFACE MOLECULES ON LSCs
One means of isolating and potentially targeting LSCs would be
to target cell-surface molecules on the cell surface which are selec-
tively or differentially expressed relative to normal tissue, in this
case the normal HSC. Such antibodies could be expressed on dif-
ferentiated normal cells but not on normal HSCs. LSCs lack Thy-1
(CD90) and c-kit (CD117), both found on normal HSCs, but they
possess CD123, CD33, and C-type lectin-like molecule-1 (CLL-1).
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Table 1 | Sample characteristics of leukemia vs. normal stem cells.
LSC HSC
Frequency Usually rare Rare
Cell cycle status Quiescent Quiescent
MDR-1 expression + +
CD34 expression + +
CD38 expression Sometimes −
HLA-DR expression − −
CD71 expression − −
CD33 expression − (Usually) −
CD117 expression − +
CD90 expression − +
CD123 expression + − (Usually)
Aldehyde dehydrogenase expression + But intermediate + (Bright)
LSC, leukemia stem cell; HSC, hematopoietic stem cell; MDR, multi-drug
resistance.
CD96, CD45, CD32, and CD25 have been shown to be preferen-
tially expressed onAML stem cells as compared with normal HSCs
(reviewed in Majeti et al., 2009). CD90 is expressed by normal
but not AML stem cells (Baum et al., 1992). LSCs do not express
human leukocyte antigen (HLA)-DR or CD71 (Blair et al., 1998).
Many of these antigens are expressed on the cell surface, allow-
ing stem cell targeting throughout the circulation without speciﬁc
delivery requirements.
ANTIGENS USED IN TARGETING AML LSCs
CD33
CD33 is a sialylated protein expressed on normal cells with
myelomonocytic differentiation, AML blasts, and some LSC pop-
ulations. Numerous antibodies to CD33 have been developed for
clinical use, including gemtuzumab ozogamicin, a recombinant
humanized anti-CD33 conjugated with calicheamicin (Hamann
et al., 2002). This conjugate induced remission in relapsed AML,
most cases being CD33+, but it also had some activity in CD33−
cases probably due in large part to the calicheamicin effects
(Jawad et al., 2010; Pollard et al., 2012). It was also able to elim-
inate promyelocytes in cases of acute promyelocytic leukemia.
While not studied directly, it was thought to differentially kill
leukemia cells and possibly LSCs, but prolonged cytopenias also
suggested in some cases that it was expressed on normal HSCs as
well (Walter et al., 2012). Gemtuzumab ozogamicin (anti-CD33
conjugated with calicheamicin) was approved for the treatment
of relapsed AML in elderly patients. Because CD33 is also
expressed on endothelial cells of certain vascular beds, toxici-
ties such as sinusoidal obstructive syndrome of liver occurred
in some cases (McDonald, 2002), leading to eventual voluntary
withdrawal of this conjugated antibody from the market. It is
still being utilized in clinical trial settings, however, so future
studies may be able to discern its effects on LSCs in states of
MRD and other therapeutic settings in leukemia (Castaigne et al.,
2012). Other antibody conjugates are also under development
(Walter et al., 2012).
CD33 is a relatively hard molecule to target due to relatively
low antigen expression (about 104 CD33 molecules/cell) and slow
conjugate internalization (Walter et al., 2012). In CML, it has been
found (Hermann et al., 2012b) that CD34+CD38−CD123+ cells
expressed signiﬁcantly higher levels of CD33 compared to nor-
mal CD34+CD38− stem cells. Levels of CD33 mRNA were also
higher. Gemtuzumabozogamicin inhibited these in long-termcul-
ture initiating cell assays, but no mention was made of inhibition
of engraftment in NOD/SCID mice, however.
CD123
CD123 is the high-afﬁnity interleukin-3 receptor alpha chain.
While it is differentially expressed on leukemia vs. normal stem
cells (Jordan et al., 2000), cord blood may express CD123 posi-
tive progenitors. CD123 has been targeted for clinical use with a
diphtheria toxin–IL-3 fusion protein (Kuo et al., 2009) andnumer-
ous additional means to target CD123 have been developed. Jin
et al. (2009) reported on a monoclonal antibody, 7G3 which tar-
gets CD123. It was able to reduce AML-LSC engraftment and
improve murine survival in models of pre-established leukemia
where the antibody showed reduced AML burden in the marrow
and periphery as well as impaired secondary transplantation after
7G3 exposure, indicating that LSCs had been inhibited. Stein et al.
(2009) used single chain Fv antibody fragments speciﬁc for CD123
designed to speciﬁcally target LSCs. This binding created two cell
death inducing molecules; one being immunotoxic through trun-
cation with a pseudomonas exotoxin and the other targeted to the
low-afﬁnity Fcγ receptor III (CD16). This construct was able to
generate potent lysis of MOLM-143, and SKNO-1 cells in ADCC
reactions. None of the CD123 targeted agents have had signiﬁcant
clinical development to date.
C-type lectin-like molecule 1
This molecule has been found to be expressed on CD34+CD38−
AML cells. Its expression trackedwith clinical remission or relapse.
It was not found on CD34+CD38− cells from normal marrow
or on cells regenerating post-chemotherapy (van Rhenen et al.,
2007). Zhang et al. (2011) have developed nanoparticles covalently
decorated with CLL-1 targeting peptides. These are loaded with
daunorubicinwhich is then internalized to LSCs but not to normal
HSCs. Other antibody means of targeting CLL-1 are also under
development (Zhao et al., 2010).
CD96
CD96 is a member of the immune globulin superfamily. It is
normally found on T-lymphocytes. It is thought to be LSC-
speciﬁc as it is found on most CD34+CD38− AML cells whereas
it is only expressed weakly in the normal counterparts (Hosen
et al., 2007). When leukemic cells were separated into CD96 pos-
itive and negative cells, only positive cells engrafted Rag-deﬁcient
mice, suggesting that this may be an LSC-speciﬁc therapeutic
target.
Anti-PR1/HLA-A2 T-cell receptor
Antibodies against PR1 induce complement-dependent cytotox-
icity against AML progenitor cells. PR1 is a HLA-A2 restricted
leukemia-associated peptide from proteinase 3 (P3) and neu-
trophil elastase (NE) recognized by anti-PR1-speciﬁc cytotoxic
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T lymphocytes which can contribute to cytogenetic remission
of AML. These cells cause speciﬁc lysis of AML, including LSCs
(Sergeeva et al., 2011).
CD44
The CD44-6v isoform is differentially expressed by AML pro-
genitor cells. An activating CD44-speciﬁc antibody was able to
eradicate AML but not normal cord blood and normal adult mar-
row engraftment in NOD/SCID mice (Jin et al., 2006). In vivo, the
effect of this antibody, H9 was limited to situations with a lower
burden of disease (Jin et al., 2006).
CD32
This antigen has been reported by Saito et al. (2010) to be differ-
entially expressed on the AML stem cell. It recognizes the FcRIIa
low-afﬁnity receptor and as such is expressed on monocytes and
other effectors of ADCC as well.
CD25
Saito et al. (2010) also described this on the AML stem cell. Either
CD32 or CD25 or both were expressed in 32/61 (53%) of patients
in AML LSCs which were able to initiate AML and were cell–cycle
quiescent and chemotherapy resistant in vivo.
CD47
CD47 is a ligand to SIRP-alpha (signal regulatory protein-alpha).
Its expression sends a “don’t eat me” message to phagocytic cells.
Blocking antibodies toCD47 enabledphagocytosis of humanAML
LSCs but not normal LSCs (Jaiswal et al., 2009). This antibody has
been found effective in a treatment model where NSG mice were
transplanted with LSCs. After 8–12 weeks the mice were treated
with control IgG or blocking antibodies to CD47. The antibodies
to CD47 resulted in rapid clearance of AML in blood and also
of marrow LSCs. There was absence of leukemia in secondary
recipients (Majeti et al., 2009). CD47 is expressed on many tissues,
and it may be more effective with chemotherapy or with mobiliz-
ing agents to facilitate phagocytosis in the peripheral circulation
(Majeti et al., 2009).
SUMMARY OF ANTIBODY TARGETING
While antibodies have been developed to target differentially
expressed surface markers on AML vs. normal cells, none of
these have had signiﬁcant impact on disease outcomes to date.
In part, this may be due to lack of complete speciﬁcity, inadequate
targeting, toxicities due to non-speciﬁcity, antigen modulation,
and subsequent resistance, or other as yet undiscovered mecha-
nisms. Despite its removal from the market in the United States,
the anti-CD33 antibody with which most experience developed,
gemtuzumab ozogamicin, has recently been tested in low doses
during induction and consolidation chemotherapy for AML and
has been found to result in superior overall and disease-free
survival when used in combination with chemotherapy (Cas-
taigne et al., 2012). LSC frequency or MRD was not measured
as part of the study, so whether this relates to stem cell tar-
geting or other mechanisms of leukemia suppression remains
uncertain.
TARGETING SIGNALING PATHWAYS IN LSCs WITH SMALL
MOLECULE INHIBITORS
One approach to eliminating the LSC would be to target pathways
regulating stem cell self-renewal, particularly if these are differ-
entially expressed in LSCs vs. HSCs (Rasheed et al., 2011). For
example, inhibitors of Wnt have been examined in CML (Bagh-
dadi et al., 2012) and notch inhibitors have been examined in ALL,
but these are also toxic to normal HSCs in some cases, indicating
a need to ﬁnd selective inhibitors or relatively selective inhibitors
for LSCs (Guzman and Jordan, 2004; Mikkola et al., 2010). Heat
shock protein inhibitors have been found to be inhibitory to AML
progenitor cells, but whether those represent true stem cells is
uncertain (Hermann et al., 2012a).
PI3K/AKT/mTOR PATHWAY
The PI3K/AKT/mTOR pathway is activated in the majority of
AML cases, but the effects of inhibiting this pathway on LSC fre-
quency have not been described in detail (Mikkola et al., 2010). In
mice,whenPTEN,normally a suppressor of the PI3K/AKT/mTOR
pathway is depleted, normal HSCs are depleted, but L-ICs are
expanded (Lee et al., 2010). The mTOR inhibitor, rapamycin,
blocks this. The depletion of Pten-deﬁcient HSCs was not caused
by oxidative stress (Peng et al., 2010).
Altman et al. (2011) have found that dual targeting of mTORC1
and mTORC2 results in potent suppressive effects on primi-
tive leukemic progenitors from AML patients. Inhibition of the
mTOR catalytic site with OSI-027, a dual mTORC1/mTORC2
inhibitor, resulted in suppression of mTORC2 and mTORC1
complexes and elicited a much more potent anti-leukemic
response than selective mTORC1 targeting with rapamycin.
Whether these inhibitors act at a true stem cell level remains
unclear.
NF-κB pathway
NF-κB has been found to be active in most AML stem cells but
not in normal lineage negative progenitors (Jordan et al., 2006).
The proteasome inhibitor, MG-132, inhibited NF-κB activation
through stabilization of its cellular inhibitor, IκB and was able
to induce apoptosis in CD34+CD38− AML cells while sparing
normal progenitors. Since that report, other inhibitors of NF-
κB such as bortezomib or speciﬁc inhibitors of IκB kinase which
phosphorylate and inactivate IκB have been developed and have
been reported to be inhibitory to AML progenitor cells (Frelin
et al., 2005). The drug parthenolide has IKB-Iκκ inhibitory activity
and is able to induce apoptosis in AML cells coincident with NF-
κB inhibition, p53 activation, and induction of reactive oxygen
species (Neelakantan et al., 2009).
Tyrosine kinase inhibitors
These have been utilized primarily to target bcr/abl, the driving
mechanism in CML. While most bcr/abl inhibitors such as ima-
tinib mesylate, nilotinib, and dasatinib eradicate most CML cells,
they are ineffective against a reservoir of quiescent LSCs (Baghdadi
et al., 2012). Inhibition of the Wnt/beta-catenin, hedgehog, and
histone deacetylases has been shown to have potential to inhibit
the CML stem cell.
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Hedgehog/smoothened pathway
Hedgehog signaling is essential for maintenance of CSCs (Zhao
et al., 2009). Loss of smoothened, an essential component of the
Hedgehog pathway, impairs HSC renewal and decreases induction
of CML by bcr/abl. Inhibition of hedgehog by cyclopamine inhib-
ited the propagation of CML. In contrast, hedgehog signaling is
not required for adult murine HSC function and hematopoiesis
(Su et al., 2012). Its role in an AML LSC is not well worked out
yet, but inhibitors of theWnt and Shh signaling pathway cause less
apoptosis in normal vs. leukemic HSCs (Hofmann et al., 2009).
Oxidative stress pathways
While states of low oxidative stress are thought to aid in mainte-
nance of stem cell quiescence, CSCs may be susceptible to agents
which induce oxidative stress. In fact, excessive production of
ROS or a deﬁciency in antioxidant pathways has been noted in
acute leukemias (Hole et al., 2011). This has not been studied
systematically as a means of differential LSC targeting.
TARGETING VASCULAR INTERACTIONS
Since LSCs as well as their blast progeny can be isolated from the
vasculature in which they circulate, it is likely that exploitation
of LSC–vascular interactions would have greater impact on tar-
geting these stem cells than would be the case in other cancers
where the stem cells do not routinely circulate except at times of
active metastasizing. Furthermore, the LSC arises in the marrow
microenvironment, an organ that is very vascular, again suggesting
a potential role for targeting leukemia/vascular interactions. In the
marrow, LSCs interact with cells, cell matrix, and soluble factors
in the microenvironmental niche (Konopleva and Jordan, 2011).
In mice, the microenvironmental niche has been characterized as
vascular and osteoblastic, but whether such distinct niches exist in
human marrow is uncertain. When leukemia cells enter the blood,
theymust traverse the endothelial cells lining themarrow sinusoids
which comprise the vascular niche, and when they return to the
marrow, they are engaged by selectins for rolling on the endothe-
lial layer after which they attach via integrins or other adhesins.
Thereafter, they transmigrate the endothelial barrier before again
lodging in the marrow niche.
Role of endothelial cells
As noted above, when LSCs and other AML cells home to marrow
or egress marrow to the peripheral circulation, they must traverse
an endothelial monolayer. These form an intact lining of mar-
row sinusoidal vessels. The homing process involves rolling on
selectin surfaces, engaging integrin or other adhesion receptors,
transmigrating the endothelial layer, and lodging in the marrow
hematopoietic niche. Chemotherapy resistant AML stem cells are
thought to engraft with the marrow endosteal region (Ishikawa
et al., 2004). Stemcell interactionswith theniche can therefore the-
oretically be disrupted at each of these steps with possible impact
on survival, proliferation, and function.
Sipkins et al. (2005), using intravital microscopy showed that
NALM-6, an ALL cell line, engrafted in microvascular domains in
the marrow. Colmone et al. (2008) demonstrated that the NALM-
6 cells actively disrupted normal vascular niches for transplanted
human CD34+ cells and caused normal CD34+ cells to leave their
niches and to engraft in alternative niches. Targeting the sup-
portive function of the vascular niche in marrow and circulation
may therefore have inhibitory activity against LSCs. Whether this
will have a differential effect as compared with normal stem cells
remains uncertain.
Targeting vascular endothelial growth factor (VEGF) and
its receptor, VEGFR2 (KDR) may inhibit both AML cells and
endothelial cell proliferation as both possess these receptors
(Ziegler et al., 1999). Marrow vascularity is increased in AML,
and targeting this vasculature may decrease AML proliferation.
The role of speciﬁc angiopoietins such as basic ﬁbroblast growth
factor or transforming growth factor-beta has not been examined
as related to AML stem cell survival, but this might also repre-
sent pathways which might be targeted to decrease proliferation
of AML cells (Folkman, 2001). It has also been demonstrated that
leukemia cells secrete factors which can enhance endothelial cell
proliferation which in turn can stimulate leukemia cell prolifer-
ation and survival (Veiga et al., 2006). Targeting endothelial cells
via inhibition of the angiopoietin–Tie2 axis (Schliemann et al.,
2007) or via combretastatins (Petit et al., 2008) might also inhibit
leukemia cell proliferation, but speciﬁcity for LSCs has not been
determined.
CXCL12 and CXCR4
The CXCL12–CXCR4 chemokine–chemokine receptor axis is
involved in AML stem cell interaction with the marrow as is
also the case with normal HSCs. CXCR4 is expressed on primary
leukemic cells, and high expression is a negative prognostic factor
(Rombouts et al., 2004). Treatment with the CXCR4 antagonist,
plerixafor, has been found to increase sensitivity of Flt-3 mutated
AML cells to the FLT3 inhibitor, sorafenib and to induce the mobi-
lization of AML cells into the peripheral blood (Zeng et al., 2009).
It is uncertain whether there is preferential mobilization of LSCs
vs. normal progenitors and bulk AML cells.
Anti-VLA-4 and anti-VCAM
The integrin–integrin receptor pair of very late antigen-4 and vas-
cular cell adhesion molecule-1 is involved in retention of AML
cells in marrow. AML blasts with higher CD49d expression have a
poorer prognosis (Matsunaga et al., 2003), but the function of very
late-antigen-4 as measured by binding of soluble VCAM-1 may be
associated with improved overall survival of patients (Becker et al.,
2009). Interactions betweenVLA-4 and ﬁbronectin orVCAM may
modulate chemotherapy response. How this impacts AML stem
cells remains uncertain. Targeting other integrin-linked pathways
may also inhibit AML stem cells (Muranyi et al., 2010).
Role of CD44
CD44 is a glycoprotein which binds to hyaluronan, selectins, and
osteopontin and has pleiotropic functions in organogenesis, cell
homing, and migration (Krause et al., 2006). High levels of the
molecule on AML cells are associated with higher relapse rates
(Quere’ et al., 2011). The anti-CD44 antibody, H90 targets LSCs in
human AML through niche disruption and with evidence of LSC
differentiation and loss of LSC self-renewal capacity as compared
with effects on normal HSCs. Jin et al. (2006) found that using an
activating monoclonal antibody to CD44, leukemic repopulation
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of NOD/SCID mice was markedly reduced probably due to inter-
ference with transport to the stem cell-supportive niches. Since
CD44 is ubiquitously expressed, it is not known if the differ-
ential effects on LSCs are due to alternative splicing or other
reasons.
Role of hypoxia
Themarrowmicroenvironment inAML is relatively hypoxic (Fiegl
et al., 2009). Under normoxic conditions, it has been found (Wang
et al., 2011) that HIF-1α signaling was selectively activated in
the stem cells of murine lymphoma and human AML. HIF-1α
shRNA and HIF-1α inhibitors abrogated the colony-forming unit
(CFU activity) of human CSCs. The inhibitor echinomycin erad-
icated serially transplantable human AML cells in xenogeneic
models by preferential elimination of leukemic-/cancer-speciﬁc
stem cells. The increased HIF-1 activity in cancer stem cells was
seen in both hypoxic and normoxic states. Rakicidin A is another
compound which may target a hypoxic microenvironment
(Yamazaki et al., 2007).
Role of selectins
Leukemic stem cells express sialylated carbohydrate ligands on
their surfaces that adhere to selectin proteins found on endothe-
lial cells. In marrow vascular beds, these selectins are constitutively
expressed. Immobilized selectin protein can be utilized as a target-
ing mechanism for cells under ﬂow and can capture some LSCs.
Mitchell et al. (2012) have utilized targeted liposomal doxorubicin
(L-DXR) functionalized with recombinant human E-selectin and
polyethylene glycol. Normal leukocytes exposed to thesemolecules
demonstrated minimal cell death, whereas leukemia cells could
be targeted. This mechanism was effective either in suspen-
sion or immobilized onto microtubular devices. P-selectin coated
microtubules have been found to enrich for some hematopoietic
progenitors from marrow through differential rolling (Narasipura
et al., 2008), and this observation may allow delivery of cytotox-
ics to cancer cells (Rana et al., 2009), but whether this will have a
differential effect on LSCs vs. other leukemia progenitors is still
unclear.
ROLE OF CELL CYCLE IN THE VASCULAR NICHE
Chemotherapy agents used to treat leukemia kill cells that are in
active cell cycle but spare LSCs which are in a quiescent state in
the marrow endosteal niche. Like normal stem cells, LSCs are pre-
dominately in a quiescent state which allows avoidance of stem
cell exhaustion and minimization of risk of oncogenic events.
Those LSCs located more centrally in the marrow cavity have a
higher likelihood of being in active cell cycle (Doan and Chute,
2012). Attempts have been made to use agents such as granulocyte
colony stimulating factor to cause LSCs to cycle, disrupting them
from their vascular niche and increasing their sensitivity to agents
such as cytarabine (Mikkola et al., 2010). Such efforts have not had
great therapeutic impacts, however (Pabst et al., 2012).
SUMMARY
The LSC, like its normal stem cell counterpart, lodges in marrow
niches and occasionally circulates in the blood. Ideally, a thera-
peutic strategy that targets LSCs must spare self-renewing normal
HSCs so as to protect ongoing hematopoiesis. The comparison of
LSCs vs. HSCs functionally is crucial to identifying unique prop-
erties of the LSC which can be targeted. These will include surface
antigen phenotyping (Amadori and Stasi, 2006), comparison of
signal transduction pathway activation, response to reactive oxy-
gen species and stress protein responses at baseline and in response
to chemotherapeutic agents. Also, understanding differences in
interactions with vasculature peripherally and in marrow may
allow for differential targeting of LSCs (Doan and Chute, 2012).
The ideal target will thus be expressed on a large fraction of LSCs,
be stable through treatment types and disease stages, be present
on cell-cycle quiescent AML-initiating cells residing within the
endosteal niche, and be non-toxic to normal HSCs. Determining
the clinical effectiveness of agents which target stem cells and prov-
ing that this is clinically relevant is hard to achieve even in AML,
but novel agents and appropriate biomarkers may allow applica-
tion of these strategies for the future (Rasheed et al., 2011). LSCs
are heterogeneous, grow in subclones which have some degree of
genetic instability, and evolve with time. Many LSC-derived sub-
clones may be undetectable at diagnosis, but after therapy, they
may become the dominant clone with relapsing disease (Nguyen
et al., 2012). Both rare cancer stem cells and dominant clones will
need to be eliminated for successful disease control (Adams and
Strasser, 2008). Understanding the interaction between LSCs and
microenvironmental componentsmay also elucidatemeans to tar-
get these rare cells (Klyuchnikov and Kroger, 2009). Due to the
heterogeneity of the LSC and the similarities between HSCs and
LSCs, many challenges remain in effective targeting of these rare
cells which are thought to require elimination if AML therapies
are to have long-term success (Krause and van Etten, 2007).
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